1. Introduction {#sec1-jcm-08-00905}
===============

Pain is an unpleasant experience with complex interactions between sensorimotoric, affective, and cognitive brain networks. As such, pain, especially chronic pain, is influenced by and interacts with physical, psychological, social, and contextual factors \[[@B1-jcm-08-00905],[@B2-jcm-08-00905],[@B3-jcm-08-00905]\]. One-fifth of the European population has moderate to severe chronic pain conditions \[[@B4-jcm-08-00905]\]. These conditions are associated with psychological distress, low health, sick leave, and high socioeconomic costs \[[@B5-jcm-08-00905]\]. Therefore, a biopsychosocial (BPS) framework should be considered in clinical practice \[[@B6-jcm-08-00905],[@B7-jcm-08-00905],[@B8-jcm-08-00905]\].

Unlike single/unimodal interventions, interdisciplinary multimodal pain rehabilitation programs (IMMRPs) for chronic pain---an interdisciplinary treatment according to the International Association for the Study of Pain (IASP)---distinguish themselves as well-coordinated complex interventions. Typically, IMMRPs are based on cognitive behavioural therapy (CBT) models (including Acceptance Commitment Therapy, ACT) and are administered over several weeks to months \[[@B9-jcm-08-00905],[@B10-jcm-08-00905],[@B11-jcm-08-00905],[@B12-jcm-08-00905]\]. The Swedish programs generally include group activities such as pain education, supervised physical activity, training in simulated environments, and CBT coordinated by an interdisciplinary team (e.g., physician, occupational therapist, physiotherapist, psychologist, and social worker) based on a BPS framework \[[@B9-jcm-08-00905],[@B10-jcm-08-00905],[@B11-jcm-08-00905],[@B12-jcm-08-00905]\]. The components of IMMRP are most often chosen based on the available evidence for unimodal interventions for chronic pain, for example, with respect to education, exercise, psychological interventions, and interventions for return to work. The core goals of rehabilitation programs in general \[[@B13-jcm-08-00905]\] and especially for patients with chronic pain \[[@B14-jcm-08-00905]\] are broad and multifactorial in combination with the individualised goals of the patient. These include increased ability to participate in valued activities such as work. Hence, IMMRP is a complex intervention \[[@B13-jcm-08-00905],[@B15-jcm-08-00905]\] and, unlike pharmacological intervention, focusses on the whole person rather than just biochemical processes, implying complex patient conditions matched with complex IMMRPs \[[@B16-jcm-08-00905],[@B17-jcm-08-00905]\]. The components of IMMRP can be active independently or interdependently \[[@B15-jcm-08-00905]\], resulting in a combination of effects explained by known and unknown mechanisms. The effects are assumed to be greater than the sum of its components \[[@B18-jcm-08-00905]\].

Systematic reviews (SRs) have generally reported higher efficacy both on a general level and for specific outcomes of IMMRP compared with single-treatment or treatment-as-usual programs \[[@B10-jcm-08-00905],[@B12-jcm-08-00905],[@B19-jcm-08-00905],[@B20-jcm-08-00905],[@B21-jcm-08-00905],[@B22-jcm-08-00905],[@B23-jcm-08-00905]\]. SRs and Randomised Controlled Trials (RCTs) may be associated with risk for bias resulting from, for example, an unrepresentative selection of patients and researcher allegiance \[[@B24-jcm-08-00905],[@B25-jcm-08-00905],[@B26-jcm-08-00905]\]. Thus, it is necessary to investigate whether the evidence obtained from SRs and RCTs can be replicated within a consecutive non-selected flow of patients in practice settings using prospective observational cohort study designs such as practice-based evidence (PBE). PBE has also been applied in the field of rehabilitation research \[[@B27-jcm-08-00905]\]. The importance of such an approach is also emphasised in the real-effectiveness medicine framework \[[@B28-jcm-08-00905]\]. IMMRPs are time consuming and expensive, even when most of the activities are group-based. From an ethical, individual, and socioeconomic perspective, it is indeed remarkable to note the lack of studies investigating effect sizes (ES) in patient populations in real-life practice settings. A recent study from two Swedish university clinics reported effect sizes of 0.51--0.61 (i.e., moderate ES) for two pain intensity variables at 12-month follow-up \[[@B29-jcm-08-00905]\]. These effect sizes should be confirmed in larger studies based not only on patients at university hospitals, but also on specialist units in general. It would be motivating for patients to endure increases in pain, which is often observed in clinical practise during the start-up period of rehabilitation characterised by an increase in activity levels, if it were known that the long-term effects include the reduction of pain levels.

Complex interventions such as IMMRP should have several outcomes measured at multiple levels and strategies for handling multiple outcomes \[[@B17-jcm-08-00905],[@B30-jcm-08-00905]\]. IMMRPs are evaluated using many outcomes. For example, one SR including 46 RCTs reported nine outcomes per RCT (median) \[[@B10-jcm-08-00905]\]. However, outcomes are not usually divided into primary and secondary outcomes \[[@B10-jcm-08-00905]\]. In addition, although it is most likely that changes in several of the selected outcomes are correlated, most SRs of IMMRPs evaluate the outcomes as independent from each other. Patterns of potential correlations (i.e., multivariate correlation patterns) are mainly unknown/uninvestigated, even though they could give valuable information regarding how to optimise IMMRPs. Hence, there is a need to develop clinically applicable ways to evaluate the multiple outcomes of MMPRs both for individual patients and within research studies.

The above knowledge gaps motivated this PBE study of chronic pain patients based on patient reported outcome measures (PROMs) from the Swedish Quality Registry for Pain Rehabilitation (SQRP) \[[@B31-jcm-08-00905]\]. This registry offers an opportunity to investigate clinical outcomes and patterns of change, since all the relevant specialist care units throughout Sweden deliver data to SQRP. Hence, this PBE study has the general aim of investigating the effects of IMMRP in specialist care in Sweden considering the multivariate complexity of outcomes. We hypothesised that IMMRP in special care is associated with small-to-medium ES, that changes in outcomes generally are intercorrelated, and that the baseline situation (pre-IMMRP) can predict the multivariate outcomes. More specifically, we defined the following four aims:To investigate the outcome effect sizes of IMMRP immediately post-IMMRP and at 12-month follow-up.To analyse the multivariate correlation patterns of changes in outcomes of IMMRP: pre-IMMRP versus post IMMRP and pre-IMMRP versus 12-month follow-up.To define a multivariate outcome measure of IMMRP.To investigate if the clinical self-reported presentation pre-IMMRP can predict the multivariate outcome measure.

2. Materials and Methods {#sec2-jcm-08-00905}
========================

2.1. The Swedish Quality Registry for Pain Rehabilitation (SQRP) {#sec2dot1-jcm-08-00905}
----------------------------------------------------------------

The SQRP, recognised by the Swedish Association of Local Authorities and Regions, receives data from all specialist care units in Sweden \[[@B31-jcm-08-00905]\]. The SQRP is based on PROM questionnaires that capture biopsychosocial data such as the patient's background, pain distribution and intensity, pain-related cognitions, and psychological distress symptoms (e.g., depression and anxiety), as well as activity/participation aspects and health-related quality of life variables. Patients complete the PROM questionnaires on up to three occasions: (1) during assessment at the first visit to the unit (pre-IMMRP); (2) immediately after the IMMRP (post-IMMRP); and (3) at the 12-month follow-up (FU) after IMMRP discharge (12-month FU).

2.2. Subjects {#sec2dot2-jcm-08-00905}
-------------

This study included SQRP data from women and men ≥18 years old with complex chronic (≥3 months) non-malignant pain who were referred to specialist pain and rehabilitation units (i.e., specialist care centres) between 2008--2016. These patients can be characterised as complex, as their health profiles included psychiatric comorbidities such as depression and anxiety, low levels of acceptance, high levels of kinesiophobia, decreased working life and participation in social activities, and/or did not respond to routine pharmacological/physiotherapeutic treatments delivered in a monodisciplinary fashion. Strict inclusion and exclusion criteria for inclusion in the registry is not available, since this is a registry study of patients with complex chronic pain conditions referred from mainly the primary care to specialist care in Sweden. A minority of patients were referred from other specialist clinics e.g., orthopedic and rheumatology clinics. The following general inclusion criteria for IMMRP were used: (i) disabling chronic pain (on sick leave or experiencing major interference in daily life due to chronic pain); (ii) age 18 years and above; (iii) no further medical investigations needed; and (iv) written consent to participate and attend IMMRP. General exclusion criteria for IMMRP included severe psychiatric morbidity, abuse of alcohol and/or drugs, diseases that did not allow physical exercise, and specific pain conditions with other treatment options available (i.e., red flags).

The proportions of patients within primary health care with chronic pain conditions are not exactly known, but 10--20% are estimates \[[@B32-jcm-08-00905],[@B33-jcm-08-00905]\]. Furthermore, the proportion of chronic pain patients within primary health care that are referred to specialist clinics is not known.

The study was conducted in accordance with the Helsinki Declaration and Good Clinical Practice and approved by the Ethical Review Board in Linköping (Dnr: 2015/108-31). All the participants received written information about the study and gave their written consent.

2.3. Variables {#sec2dot3-jcm-08-00905}
--------------

Background variables that were collected pre-IMMRP and symptom-related self-reported variables that were collected at all three times (pre, post, and 12-month FU) were used in the analyses. The variables and instruments used are mandatory for the units registering their data with the SQRP.

### Background Variables

The following background variables were collected: age (years), gender (man or woman), education level, and country of birth. Education level was dichotomised into university and the other alternatives (i.e., upper secondary school, elementary school, or other); this variable was labelled as University. Country of birth was dichotomised as from Europe and outside Europe and labelled as Outside-Europe. In addition, self-reported pain duration (days), persistent pain duration (days), and number of days off work (Days no work) were obtained.

Pain distribution was registered using 36 predefined anatomical areas (18 on the front and 18 on the back of the body) and the patients registered the areas with pain: (1) head/face, (2) neck, (3) shoulder, (4) upper arm, (5) elbow, (6) forearm, (7) hand, (8) anterior aspect of chest, (9) lateral aspect of chest, (10) belly, (11) sexual organs, (12) upper back, (13) low back, (14) hip/gluteal area, (15) thigh, (16) knee, (17) shank, and (18) foot. The number of areas with pain (range: 1--36) were summed, and the obtained variable was denoted as the Pain Region Index (PRI).

2.4. Repeated Self-Reported Measures {#sec2dot4-jcm-08-00905}
------------------------------------

For reports of the psychometric aspects of the self-reported measures, the reader is referred to other studies summarising these \[[@B7-jcm-08-00905],[@B34-jcm-08-00905],[@B35-jcm-08-00905],[@B36-jcm-08-00905]\].

### 2.4.1. Pain Aspects {#sec2dot4dot1-jcm-08-00905}

Pain intensity average during the previous seven days was registered using a 0--10 (0 = no pain and 10 = worst possible pain) numeric rating scale (NRS)---NRS-7days.

### 2.4.2. The Multidimensional Pain Inventory (MPI) {#sec2dot4dot2-jcm-08-00905}

MPI is a 61-item self-report questionnaire that measures the psychosocial, cognitive, and behavioural effects of chronic pain \[[@B37-jcm-08-00905],[@B38-jcm-08-00905]\]. Part 1 consists of five scales: Pain severity---measuring several aspects of the pain experience (MPI-Pain-severity); Interference---pain-related interference in everyday life (MPI-Pain-interfer); Perceived Life Control (MPI-LifeCon); the level of affective distress (MPI-Distress); and Social Support---perceived support from a spouse or significant others (MPI-SocSupp). Part 2 assesses the perception of responses to displays of pain and suffering from significant others and consists of three scales: Punishing Responses (MPI-Punish); Solicitous Responses (MPI-Solict); and Distracting Responses (MPI-Distract). Part 3 measures to what extent the patients participate in various activities using four scales. These scales can be combined into a composite scale---the General Activity Index (MPI-GAI)---which was used in the present study \[[@B39-jcm-08-00905]\].

### 2.4.3. Psychological Distress Variables {#sec2dot4dot3-jcm-08-00905}

Symptoms of anxiety and depression were registered using the Hospital Anxiety and Depression Scale (HADS) \[[@B40-jcm-08-00905],[@B41-jcm-08-00905]\]. This instrument comprises seven items in each of two subscales: depression (HADS-D) and anxiety (HADS-A) symptoms. Both subscale scores have a range of 0 to 21. A score of 7 or less in each subscale indicates a non-case, a score of 8--10 indicates a possible case, and a score of 11 or more indicates an almost definite case \[[@B40-jcm-08-00905]\].

### 2.4.4. The Short Form Health Survey (SF36) {#sec2dot4dot4-jcm-08-00905}

The Short Form Health Survey (SF36) attempts to represent multidimensional health concepts and measurements of the full range of health states, including levels of well-being and personal evaluations of health \[[@B42-jcm-08-00905]\]. Scores are standardised into eight dimensions with a scale from 0 to 100 where higher scores indicate a better perception of health \[[@B42-jcm-08-00905]\]: (1) physical functioning (sf36-pf), physical activity level including activities of daily living; (2) role limitations due to physical functioning (sf36-rp), to what extent physical health limits the performance of work and other regular activities; (3) bodily pain (sf36-bp), pain and related disability; (4) general health (sf36-gh), evaluation of health situation; (5) vitality (sf36-vt), how rested and energetic; (6) social functioning (sf36-sf), disturbances of social life due to physical or mental illness; (7) role limitations due to emotional problems (sf36-re), difficulties in performing work or other regular activities due to emotional problems; and (8) mental health (sf36-mh), anxiety and depressive symptoms. Based on the eight scales, a physical summary component and a mental (psychological) summary component can be calculated, but these two summary component variables were not used in the present study.

### 2.4.5. The European Quality of Life Instrument (EQ-5D) {#sec2dot4dot5-jcm-08-00905}

The European Quality of Life Instrument (EQ-5D) captures a patient's perceived state of health \[[@B43-jcm-08-00905],[@B44-jcm-08-00905],[@B45-jcm-08-00905]\]. The first part of the instrument defines five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of these were measured at three levels. An EQ-5D-index is derived by applying a formula that essentially attaches values (weights) to each of the levels in each dimension. The collection of index values (weights) for all the possible EQ-5D states is called a value set. Most EQ-5D value sets have been obtained from a standardised valuation exercise where a representative sample of the general population in a country/region is asked to place a value on EQ-5D health states. The EQ5D also measures the self-estimation of today's health according to a 100-point scale, which is a thermometer-like scale (EQ-VAS) with defined end points (high values indicate good health and low values indicate bad health).

### 2.4.6. Estimations of Changes in Pain and in Life Situation {#sec2dot4dot6-jcm-08-00905}

The patients post-IMMRP and at the 12-month FU estimated the degree of positive change in pain (Change-pain) and in their ability to handle life situations in general (Change-life situation). The Change-pain item was rated on a five-point Likert scale from markedly increased pain (0) to markedly decreased pain (4). The Change-life situation item was rated on a five-point Likert scale from markedly worsened (0) to markedly improved (4).

2.5. Statistics {#sec2dot5-jcm-08-00905}
---------------

All the statistics were performed using the statistical package IBM SPSS Statistics (version 24.0) and SIMCA-P+ (version 15.0; Umetrics Inc., Umeå, Sweden). A probability of \<0.001 (two-tailed) was accepted as the criteria for significance due to the large number of subjects.

The text and tables generally report the mean value ± one standard deviation (±1 SD) together with a median and range of continuous variables. Percentages (%) are reported for categorical variables. The detailed analyses also report 95% confidence intervals (95% CI). SQRP uses predetermined rules when handling single missing items of a scale or a subscale; details about this have been reported elsewhere \[[@B29-jcm-08-00905]\]. To compare groups, we used Student´s *t*-test for unpaired observations, analysis of variance (ANOVA with post hoc test if significant difference), and Chi square test. Effect sizes (ES; Cohen's d) for within-group analysis were computed using a calculator when appropriate (<https://webpower.psychstat.org/models/means01/effectsize.php>). Hedges' g, which provides a measure of effect size weighted according to the relative size of each sample, was used for between ES using a calculator (<https://www.socscistatistics.com/effectsize/default3.aspx>). The absolute effect size was considered very large for values ≥ 1.3, large for values between 0.80--1.29, moderate for values between 0.50--0.79, small for values between 0.20--0.49, and insignificant for values \< 0.20 \[[@B46-jcm-08-00905]\].

Common methods such as logistic regression (LR) and multiple linear regression (MLR) can quantify the level of relations of individual factors but disregard interrelationships among different factors and thereby ignore system-wide aspects \[[@B47-jcm-08-00905]\]. Moreover, such methods assume variable independence when interpreting results \[[@B48-jcm-08-00905]\], and there are several risks when considering one variable at a time \[[@B49-jcm-08-00905]\]. To account for our aims, the problems related to handling missing data (see below), and the risks associated with multicollinearity problems (see above), we used advanced multivariate analyses (MVDA).

Hence, using SIMCA-P+, we applied advanced Principal Component Analysis (PCA) for the multivariate correlation analyses of all investigated variables and Orthogonal Partial Least Square Regressions (OPLS) for the multivariate regressions. These techniques do not require normal distributions of the included variables \[[@B50-jcm-08-00905]\]. Note that the PCA of SIMCA-P+ differs considerably from the simpler version implemented (e.g., the version used in SPSS).

PCA extracts and displays systematic variation in the data matrix. All the variables were log transformed before the statistical analyses if data were skewed. Using PCA, we analysed the multivariate correlation pattern for the changes in the 22 outcome variables for all the subjects. Note that changes in outcomes are calculated so that a positive value indicates an improvement. A cross-validation technique was used to identify nontrivial components (p). Variables loading on the same component p were correlated, and variables with high loadings but with opposing signs were negatively correlated. Variables with high absolute loadings were considered significant. The obtained components are per definition not correlated and are arranged in decreasing order with respect to explained variation. The loading plot reports the multivariate relationships between variables. A corresponding plot reporting the relationships between subjects (i.e., *t*-scores) can also be used (score plot), and each subject receives a score (*t*) for each of the significant components. The *t*-score was used to calculate a Multivariate Improvement Score (MIS). R^2^ describes the goodness of fit---the fraction of sum of squares of all the variables explained by a principal component \[[@B51-jcm-08-00905]\]. Q^2^ describes the goodness of prediction---the fraction of the total variation of the variables that can be predicted using principal component cross-validation methods \[[@B51-jcm-08-00905]\]. Outliers were identified using two methods: score plots in combination with Hotelling's T^2^ and distance to model in the X-space. No extreme outliers were detected.

OPLS was used for the longitudinal multivariate regression analyses of the *t*-scores of the PCA mentioned above using pre-IMMRP data (i.e., baseline data) \[[@B51-jcm-08-00905]\]. The variable influence on projection (VIP) indicates the relevance of each X-variable pooled over all dimensions and Y-variables---the group of variables that best explain Y. VIP ≥ 1.0 was considered significant if VIP had a 95% jack-knife uncertainty confidence interval non-equal to zero. p(corr) was used to note the direction of the relationship (positive or negative). This is the loading of each variable scaled as a correlation coefficient, and thus standardising the range from −1 to +1. \[[@B50-jcm-08-00905]\] p(corr) is stable during iterative variable selection and comparable between models \[[@B50-jcm-08-00905]\]. Thus, a variable/regressor was considered significant when VIP \> 1.0. For each regression, we report R^2^, Q^2^, and the *p*-value of a cross-validated analysis of variance (CV-ANOVA). SIMCA-P+ uses the Non-linear Iterative Partial Least Squares (NIPALS) algorithm to handle missing data: maximum 50% missing data for variables/scales and maximum 50% missing data for subjects.

To identify clusters based on the *t*-scores of the PCA mentioned above, we performed hierarchical clustering analysis (HCA). Based on the identified clusters (subgroups) defined by HCA, we performed partial least squares discriminant analysis (PLS-DA). In addition, we applied a bottom--up HCA to the principal component score vectors using the default Ward linkage criterion to identify relevant subgroups of patients. HCA can find subtle clusters in the multivariate space. In the resulting dendrogram, clusters were identified and, based on these groups, we performed PLS-DA using group belonging as the Y-variable and the psychometric data as predictors (X-variables). The PLS-DA model was computed to identify associations between the X-variables and the subgroups. Based on the HCA defined clusters, traditional inferential statistics (ANOVA including post hoc tests when appropriate) were computed using SPSS.

3. Results {#sec3-jcm-08-00905}
==========

3.1. Background Data {#sec3dot1-jcm-08-00905}
--------------------

There were 14,666 chronic pain patients registered in the SQRP that fulfilled the inclusion criteria: chronic pain; \>18 years of age; and completed the SQRP questionnaire before and on at least one of the two time points after the IMMRP. More than half (60%) of the patients answering the questionnaires pre-IMMRP and post-IMMRP also answered the questionnaires at 12-m FU. Most of the patients (76.3%) were women, 25.2% had studied at university, and 10.4% were born outside of Europe. More men were born outside Europe (men: 13.4% versus women: 9.5%; Chi^2^ = 43.437, *p* \< 0.001), and fewer men had university education (men: 18.0% versus women: 27.4%; Chi^2^ = 123.672; *p* \< 0.001). Continuous background variables are shown in [Table 1](#jcm-08-00905-t001){ref-type="table"}. Women were slightly younger than men (42.9 ± 10.7 versus 44.5 ± 10.7; *p* \< 0.001) and reported more spreading of pain according to PRI (15.4 ± 8.8 versus 10.8 ± 7.0; *p* \< 0.001). The other variables in [Table 2](#jcm-08-00905-t002){ref-type="table"} were not affected by gender.

3.2. Pairwise Comparisons of Repeated Measures {#sec3dot2-jcm-08-00905}
----------------------------------------------

The results for pre-IMMRP and post-IMMRP are shown in [Table 2](#jcm-08-00905-t002){ref-type="table"}. Significant improvements were generally found except for two of the three scales of the second part of the MPI. In addition, the comparisons between pre-IMMRP and the 12-month FU generally revealed significant improvements except for one of the scales on the second part of the MPI ([Table 3](#jcm-08-00905-t003){ref-type="table"}). Some outcomes were associated with moderate effect sizes. For the pre-IMMRP versus post-IMMRP comparisons, three variables had moderate effects sizes: MPI-pain-severity, sf36-bp, and sf36-vt ([Table 2](#jcm-08-00905-t002){ref-type="table"}). At the 12-month FU, MPI-pain-severity and sf36-bp were associated with moderate effect sizes; this was also the case for MPI-pain-interference and EQ5d-index ([Table 3](#jcm-08-00905-t003){ref-type="table"}). However, generally small effect sizes were found for the significant improvements ([Table 2](#jcm-08-00905-t002){ref-type="table"} and [Table 3](#jcm-08-00905-t003){ref-type="table"}). The variables of the second part of the MPI had insignificant effect sizes both post-IMMRP and 12-month FU.

3.3. Patients Not Participating in the 12-Month FU {#sec3dot3-jcm-08-00905}
--------------------------------------------------

There were only small differences between those reporting PROM data at the 12-month FU and those not reporting their situation pre-IMMRP ([Supplementary Table S1](#app1-jcm-08-00905){ref-type="app"}). Although those not reporting had a somewhat worse situation for most of the PROM variables, the differences were of no clinical importance.

3.4. Estimations of Changes in Pain and in Life Situation {#sec3dot4-jcm-08-00905}
---------------------------------------------------------

At both post-IMMRP and 12-month FU, most patients reported that their pain situation had improved as well as their ability to handle their life situation ([Table 4](#jcm-08-00905-t004){ref-type="table"}).

3.5. Multivariate Correlation Pattern of Changes in Outcomes {#sec3dot5-jcm-08-00905}
------------------------------------------------------------

PCAs of the changes (i.e., the difference) were performed for pre-IMMRP versus post-IMMRP and pre-IMMRP versus 12-month FU. Significant models were achieved for both analyses ([Table 5](#jcm-08-00905-t005){ref-type="table"}). Similar patterns were obtained for the first significant component of the two PCAs ([Table 5](#jcm-08-00905-t005){ref-type="table"}). The first component of both analyses, reflecting the most important variations, showed that changes in HAD-D, MPI-pain-severity, MPI-pain interference, MPI-control, MPI-distress, sf-36-bp, sf-36-vt, sf-36-sf, and sf36-mh were most important and intercorrelated significantly. Hence, it was obvious that the changes in outcome variables are intercorrelated. That is, rather than representing 22 independent variables, the multivariate analyses show that most changes in these variables are highly intercorrelated.

At 12-month FU, the PCA also identified two additional components ([Table 5](#jcm-08-00905-t005){ref-type="table"}). The second component mainly reflected the intercorrelation pattern between the social support scale of the MPI and the scales of part 2 of the MPI. A third significant component only explaining 6% of the variation in the dataset was also obtained in the analysis of changes at the 12-month follow-up versus baseline ([Table 5](#jcm-08-00905-t005){ref-type="table"}).

The loading plot (i.e., the intercorrelations between variables of the two most important components for the changes pre IMMRP versus 12-month FU) is shown in [Figure 1](#jcm-08-00905-f001){ref-type="fig"} ([Figure 1](#jcm-08-00905-f001){ref-type="fig"}a is a graphic presentation of the first two components reported in [Table 5](#jcm-08-00905-t005){ref-type="table"}). [Figure 1](#jcm-08-00905-f001){ref-type="fig"}b shows the corresponding score plot (i.e., the relationships between subjects/patients). Each patient can be described with a score (*t*-score) for each significant component. Patients with high positive *t*-scores on the first component show prominent changes in the important variables constituting the first component, whereas patients near zero do not benefit, and patients with negative *t*-scores (located to the left in the score plot) deteriorate in the multivariate context. Hence, the *t*-score of the first component of both analyses can be considered as a Multivariate Improvement Score, in the following denoted MIS-post-IMMRP and MIS-12-month FU.

3.6. Identification of Subgroups Based on the Multivariate Improvement Scores (MIS) {#sec3dot6-jcm-08-00905}
-----------------------------------------------------------------------------------

An HCA based on MIS-post-IMMRP was performed. Three subgroups/clusters were identified. Based on the HCA, a PLS-DA model with two predictive components was obtained with group belonging as the Y-variable (R^2^ = 0.35; Q^2^ = 0.35; CV-ANOVA *p* \< 0.001; *n* = 14,666). Using a similar approach, we performed an HCA based on MIS-12-month FU. This analysis identified three subgroups/clusters. Based on the HCA, a PLS-DA model with two predictive components was obtained with group belonging as the Y-variable (R^2^ = 0.37; Q^2^ = 0.37; CV-ANOVA *p* \< 0.001; *n* = 8851).

The MIS (i.e., *t*-score) showed clear positive values (i.e., improvements) for cluster 1 and negative scores (i.e., deterioration) for cluster 3 ([Table 6](#jcm-08-00905-t006){ref-type="table"} and [Table 7](#jcm-08-00905-t007){ref-type="table"}). Cluster 2 was an intermediary cluster with overall slightly positive improvements. Prominent effect sizes in the pairwise comparisons were observed post-IMMRP: cluster 1 versus cluster 2 = 3.33; cluster 1 versus cluster 3 = 5.36; and cluster 2 versus cluster 3 = 2.77; 12-month FU: cluster 1 versus cluster 2 = 2.92; cluster 1 versus cluster 3 = 4.99; and cluster 2 versus cluster 3 = 2.34. Thus, distinct differences in improvement levels were detected between the three clusters.

To facilitate the understanding of the identified clusters, the clusters were compared for the variables in each PCA ([Table 6](#jcm-08-00905-t006){ref-type="table"} and [Table 7](#jcm-08-00905-t007){ref-type="table"}). The three clusters differed significantly for all changes according to the ANOVAs performed. The post hoc tests showed that 20 of the 22 changes post-IMMRP differed significantly between all three clusters. The corresponding figure at 12-month FU was 21 of 22 changes.

The estimations of changes in pain (Change-pain) and in management of life (Change-life situation) were not included in the PCAs and thus not included in the calculations of MIS. However, these estimations showed a similar pattern: the most prominent positive changes were in cluster 1, and the least positive changes were in cluster 3 ([Table 6](#jcm-08-00905-t006){ref-type="table"} and [Table 7](#jcm-08-00905-t007){ref-type="table"}).

In the next step, the identified three clusters of both analyses were compared for their pre-IMMRP values ([Table 8](#jcm-08-00905-t008){ref-type="table"} and [Table 9](#jcm-08-00905-t009){ref-type="table"}). For the clusters obtained post-IMMRP ([Table 8](#jcm-08-00905-t008){ref-type="table"}), small irrelevant cluster differences existed for age. The proportion with university education was significantly highest in cluster 1 and lowest in cluster 3, although the differences were small. Generally, cluster 1 was associated with the worst situation for the most variables followed longitudinally except for social support, two of the scales of [Section 2](#sec2-jcm-08-00905){ref-type="sec"} of the MPI, and sf36-pf. In contrast, cluster 3 had the best situation, and cluster 2 was intermediate ([Table 8](#jcm-08-00905-t008){ref-type="table"}). A very similar pattern was found when using the clusters obtained from the 12-month FU ([Table 9](#jcm-08-00905-t009){ref-type="table"}).

3.7. Longitudinal Regression of MIS Using Baseline Data {#sec3dot7-jcm-08-00905}
-------------------------------------------------------

The outcome data at baseline (pre-IMMRP) together with the background variables were used to regress MIS-post-IMMRP and MIS-12-month FU ([Table 10](#jcm-08-00905-t010){ref-type="table"}). For both MIS, psychological distress variables were the most important regressors, but life impact variables, pain aspects, and health and vitality aspects contributed significantly. The directions of the correlations revealed that a more severe clinical situation (e.g., psychological distress, lack of control, low vitality and health, pain interference, and high pain intensity) were associated with high MIS (i.e., multivariate improvements). Although the obtained regressions were highly significant according to the CV-ANOVA, the explained variations in MIS were less than 10% (R^2^ = 0.08 in both analyses). Hence, most of the variations in the two MIS were not possible to predict.

Similar analyses for each of the clusters ([Supplementary Tables S2 and S3](#app1-jcm-08-00905){ref-type="app"}) revealed that regressions were highly significant, but only explained a minority of the variations in MIS. Although the relative importance of the variables pre-IMMRP differed somewhat between the three clusters, no marked differences existed; that is, psychological distress aspects were the most important post-IMMRP ([Supplementary Table S2](#app1-jcm-08-00905){ref-type="app"}). For the 12-month FU, somewhat more pronounced differences existed between the clusters: in cluster 2, the pain intensity aspects were the most important for MIS, and in cluster 1 and cluster 3, psychological distress variables together with pain interference were the most important for MIS.

4. Discussions {#sec4-jcm-08-00905}
==============

The major findings of the present large PROM study from SQRP are listed below:Moderate long-term ES were found for pain intensity (MPI Pain severity and SF-36 bodily pain), interference in daily life (MPI Interference), and state of health (EQ-5D-index); most other variables showed small ES. Vitality also displayed moderate effect sizes immediately after IMMRP but fell slightly under cut-off for moderate change at 12-month follow-up. The majority of the 22 investigated outcomes were significantly improved.Significant intercorrelations between changes in pain intensity, interference, control, psychological distress, and mental health were confirmed. The changes in 22 outcomes reflected one (pre-IMMRP versus post-IMMRP) or three (pre-IMMRP versus 12-month follow-up) latent components (groups of variables).The outcomes were best for patients with the worst self-reported clinical presentation pre-IMMRP. Based on a defined multivariate improvement score (MIS), three clusters were identified. Cluster 1---overall, the worst situation pre-IMMRP---showed positive multivariate improvements in outcomes. Cluster 3---deteriorated---showed negative scores. Cluster 2, the intermediate cluster, was associated with overall slightly positive multivariate improvements.Certain variables (especially psychological distress and life impact variables, pain, and health and vitality aspects) pre-IMMRP were associated with improvements according to MIS both post-IMMRP and at 12-month FU. However statistically significant, the pre-IMMRP situation could only explain a small part of the variation in MIS (8%); therefore, for clinical use, it was not possible to predict those who would benefit most from IMMRP.

The outcome variables mandatory in SQRP and presented in the present study are in good agreement with the BSP model of chronic pain and the outcome domains presented by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) \[[@B7-jcm-08-00905],[@B52-jcm-08-00905]\] and the Validation and Application of a patient-relevant core set of outcome domains to assess multimodal PAIN therapy (VAPAIN) \[[@B14-jcm-08-00905]\] initiatives.

The present study was not primarily designed to evaluate the efficacy of IMMRP, which requires RCTs and SRs/meta-analyses. However, our results for the repeated measurements ([Table 2](#jcm-08-00905-t002){ref-type="table"} and [Table 3](#jcm-08-00905-t003){ref-type="table"}) of chronic pain patients in real-life practice settings are in agreement with the positive evidence for IMMRPs reported in SRs \[[@B10-jcm-08-00905],[@B11-jcm-08-00905],[@B12-jcm-08-00905]\] and in other studies \[[@B22-jcm-08-00905],[@B23-jcm-08-00905],[@B53-jcm-08-00905]\]. As such, the small to moderate ES are noteworthy as these patients, who receive pain rehabilitation in specialist care centres, often have tried other treatments for their chronic pain with no or little effect. That is, these patients have severe problems and relative treatment resistance. Interestingly, the changes in outcomes with moderate ES are broad and not limited to a single outcome domain, and the most stable moderate ES were demonstrated for pain intensity aspects with moderate improvement both immediately after IMMRPs and at 12-month follow-up. Pain interference demonstrated moderate ES improvement at 12-month follow-up, and vitality was moderately improved immediately after IMMRPs. Both objective registrations (e.g., sick-leave registrations and actigraphic recordings \[[@B54-jcm-08-00905]\]) and subjective PROM data may be important for understanding the efficacy of IMMRPs. Very recently, a SQRP study using a subgroup of the same cohort of patients reported that sick leave benefits according to the Swedish Social Insurance Agency decreased as a consequence of IMMRP \[[@B55-jcm-08-00905]\]. Hence, both PROM data and objective sick leave data indicate clinically important positive changes in response to IMMRPs for patients in real-life practice settings. As a comparison, SRs conclude that common pharmacological treatments---e.g., paracetamol, non-steroidal anti-inflammatory drugs, and opioids---for patients with chronic pain have no effects, small effects, and/or lack of long-term follow-up effects \[[@B56-jcm-08-00905],[@B57-jcm-08-00905],[@B58-jcm-08-00905]\].

The present study reported medium ES for two of three pain intensity variables both post-IMMRP and at 12-month FU (i.e., for MPI-pain-severity and sf36-bp); the third pain intensity variable had effect sizes near medium ES. These results contrasted some SRs reporting of no evidence for efficacy with respect to pain intensity \[[@B10-jcm-08-00905],[@B11-jcm-08-00905]\]. However, not all RCTs of IMMRP included pain intensity outcomes, since the interventions are not focused on the pain itself but rather on its consequences \[[@B10-jcm-08-00905],[@B11-jcm-08-00905]\]. Obviously, many pain patients consider pain intensity improvement to be the most important aspect of treatments \[[@B59-jcm-08-00905]\]. However, changing this perspective is considered important in IMMPRs, since focusing on pain reduction in many cases leads to short-sighted attempts to control pain, and this may, when not successful, lead to increased physical and psychological disability and reduced life quality \[[@B60-jcm-08-00905],[@B61-jcm-08-00905]\]. Thus, specialist care IMMRPs in Sweden have largely adopted the idea of introducing acceptance as a cornerstone of the psychological component of IMMRP (i.e., the willingness to have the experiences of pain as it is and to encourage patients to set up activity-related rehabilitation goals and risk initial pain flare-ups). This also means that patients are advised against establishing pain reduction goals. Thus, it could be considered problematic to communicate the present results showing medium effect sizes in real-world practice settings on pain. On the other hand, it may also be ethically problematic if both clinical practice and research ignore the reports and wishes of the patients regarding pain intensity. However, health care providers should not underestimate their patients' ability to grasp, once explained, the complex pain experience. Therefore, health care providers should emphasise pain education, including descriptions of the affective and cognitive elements of pain as rational for the different components of IMMRPs, and stress the need to experiment with new behaviours and risk short-term pain flare-ups. Since the results are obtained in this context, no change in clinical practise as far as pain communication is called for.

SRs of IMMRP report that it is an effective intervention with small to moderate effects for patients with chronic pain conditions \[[@B11-jcm-08-00905],[@B12-jcm-08-00905],[@B62-jcm-08-00905],[@B63-jcm-08-00905]\]. The present results concerning ES agree with most SRs of IMMRP, but it may also be appropriate to compare with ES results reported in other clinical studies. The moderate ES for two of the pain intensity variables agree with studies in clinical routine care (n = 65--395), and therefore, for long-term follow-up (6--12 months), such studies report small (Cohen's d: 0.20--0.33 \[[@B64-jcm-08-00905],[@B65-jcm-08-00905]\]) to moderate (Cohen's d: 0.59--0.70 \[[@B26-jcm-08-00905],[@B66-jcm-08-00905],[@B67-jcm-08-00905]\]) ES for pain intensity. For psychological distress variables, these studies agree with the present results: they generally found small ES for long-term follow-up (i.e., Cohen's d = 0--0.38 for depressive symptoms \[[@B26-jcm-08-00905],[@B64-jcm-08-00905],[@B65-jcm-08-00905]\] and Cohen's d = 0.22--0.34 for anxiety) \[[@B26-jcm-08-00905],[@B65-jcm-08-00905]\]. In a recent RCT comparing transdiagnostic emotion-focused exposure treatment (Hybrid) and Internet-delivered pain management treatment (ICBT) for chronic pain patients with comorbid anxiety and depression, we found that within group ES pre versus follow-up for pain interference were reported both for hybrid (ES = 1.17) and for ICBT (ES = 0.65) compared the present effect size of 0.49 \[[@B68-jcm-08-00905]\]. However, the patients were not exclusively recruited from specialist care (i.e., clinical departments of pain rehabilitation); they were also recruited via advertisements in local newspapers and social media \[[@B68-jcm-08-00905]\], and the numbers investigated were considerably smaller. An important observation from the present study is that moderate ES found at 12-month follow-up covered broad aspects (e.g., pain intensity, interference in daily life, and perceived health).

The number of outcomes in IMMRPs in RCTs are generally high, which reasonably reflects the broad goals of the complex intervention. The present study used 22 outcomes that are mandatory in SQRP measured on up to three occasions (i.e., pre-IMMRP, post-IMMRP, and 12-month follow-up). PCA was applied to handle the pattern of changes in potentially intercorrelated outcomes as suggested by the Medical Research Council of the United Kingdom \[[@B69-jcm-08-00905]\]. From these analyses, it can be concluded that changes in pain intensity, pain interference, psychological distress, vitality, etc. were positively intercorrelated ([Table 5](#jcm-08-00905-t005){ref-type="table"}). In fact, our study showed that the changes in the majority of the 22 outcomes are significantly intercorrelated. Hence, the changes in these variables cannot be considered independent of each other. As a consequence of this observation, the appropriateness to evaluate changes in outcomes separately, as done in a recent SR \[[@B70-jcm-08-00905]\], must be questioned, since the treatment was not designed to target only a single outcome. Moreover, the ES must be seen in this complex context. Thus, small changes in many outcomes may be more important than one prominent change in a single or few outcomes. Furthermore, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) used for evidence ratings in SRs may not adequately describe the evidence base of complex interventions \[[@B71-jcm-08-00905]\]. Different definitions of positive outcomes of IMMRP interventions exist (e.g., the majority of outcomes had to be significantly better than for the control intervention) \[[@B10-jcm-08-00905],[@B11-jcm-08-00905]\]. Another approach was that the authors of the SR predetermined primary and secondary outcomes and what was necessary to classify an intervention as positive before reviewing the RCTs \[[@B12-jcm-08-00905]\].

The presented PCAs also highlight that it may be possible to reduce the number of outcome variables, since several of these appear to measure similar aspects of the chronic pain condition. The fact that 22 outcomes were analysed ([Table 2](#jcm-08-00905-t002){ref-type="table"} and [Table 3](#jcm-08-00905-t003){ref-type="table"}) may raise an issue of multiple comparisons. In such situations, Bonferroni corrections are frequently used \[[@B72-jcm-08-00905],[@B73-jcm-08-00905]\]. This is a conservative approach when the number of tests increases \[[@B72-jcm-08-00905],[@B74-jcm-08-00905],[@B75-jcm-08-00905]\], the chances to detect real treatment effects decrease, and corrections were designed for corrections of *independent* comparisons \[[@B74-jcm-08-00905]\]. The latter is obviously not present for most changes in outcome variables according to the PCAs performed ([Table 5](#jcm-08-00905-t005){ref-type="table"}). Hierarchal or 'gatekeeping' procedures do not require adjustment for multiplicity \[[@B73-jcm-08-00905]\], but require a natural hierarchy of the outcomes, as such a hierarchy is not obvious for IMMRP, as discussed above. Another approach is that outcomes are combined into a single composite outcome (i.e., a composite outcome consists of two or more component outcomes) \[[@B76-jcm-08-00905]\], but this may be problematic with respect to missing cases and when the components of the composite endpoint are measured on different scales (i.e., non-commensurate outcomes) \[[@B76-jcm-08-00905]\]. However, some multivariate methods such as PCA and OPLS can handle non-commensurate outcomes \[[@B76-jcm-08-00905]\]. We used advanced PCA, including the NIPALS algorithm, to handling missing data and non-commensurate outcomes. We calculated the *t*-scores for the most relevant latent factor (component). Hence, we defined an objective Multivariate Improvement Score (MIS; the *t*-score of the first PCA component), which on an individual patient level defines the multivariate improvement; a positive MIS indicates multivariate improvements because of IMMRP.

Three clearly separated clusters based on MIS were identified. On a group level, clusters 1 and 2 were associated with various degrees of improvements, whereas cluster 3 showed negative MIS, indicating deterioration. Although the greater improvement in cluster 1 can be interpreted as a sign of regression to the mean and that these patients did not benefit from IMMRP more than cluster 2, this cluster still improves from IMMRP at least as well as those with e.g., less severe psychological distress symptoms (clusters 2 and 3). This may seem unexpected, but it is important to recognise that addressing psychological symptoms with CBT is an important component of IMMRPs. The patients at post-IMMRP and 12-month follow-up estimated the degree of positive change in pain (i.e., Change-pain) and the ability to handle life situation in general (i.e., Change-life situation). Most patients reported improvements according to both the Change-pain and Change-life situations ([Table 4](#jcm-08-00905-t004){ref-type="table"}). Relatively small proportions of the patients reported worse situations post-IMMRP and at the 12-month follow-up, which are results that agree with other studies \[[@B29-jcm-08-00905],[@B77-jcm-08-00905],[@B78-jcm-08-00905]\]. These two variables have retrospective elements even though they are not explicitly expressed. There are several problems with such items in general---e.g., desirability and memory aspects, recall time \[[@B79-jcm-08-00905],[@B80-jcm-08-00905],[@B81-jcm-08-00905]\], and in treatment context (e.g., overly optimistic assessments) \[[@B82-jcm-08-00905]\]. However, on a general level, these estimations and the two MIS variables ([Table 6](#jcm-08-00905-t006){ref-type="table"} and [Table 7](#jcm-08-00905-t007){ref-type="table"}) agreed.

We found that cluster 1, which had high MIS values (i.e., prominent improvements), had a more severe clinical picture at baseline/pre-IMMRP than those with lower MIS (i.e., less improvements). These results agree with another SQRP study (*N* \> 35,000) that identified clusters based on the clinical presentation at assessment (decision not taken about participation in IMMRP); the study found that patients with the most severe clinical situation who later participated in IMMRP had the most prominent improvements in six investigated outcomes \[[@B34-jcm-08-00905]\]. Although IMMRP has been commended for its effectiveness ('of all approaches to the treatment of chronic pain, none has a stronger evidence basis for efficacy, cost-effectiveness, and lack of iatrogenic complications') \[[@B83-jcm-08-00905]\], both this and our recent study \[[@B34-jcm-08-00905]\] indicate that not all patients show important improvements in several domains of outcome after IMMRP. Both this and our previous study identified a large subgroup of patients that do not seem to significantly benefit from IMMRP. Presumably, these patients---in the present study, those with negative MIS (i.e., cluster 3)---need other interventions. In a relative context, they have a somewhat less complicated self-reported clinical picture pre-IMMRP than those in clusters 1 and 2, even though they are referred to specialist care and hence represent patients with complex needs.

The longitudinal regressions of MIS using background variables and pre-IMMRP data as regressors were significant ([Table 10](#jcm-08-00905-t010){ref-type="table"}). A blend of variables was important; psychological distress variables were most important, but life impact variables, pain aspects, and health and vitality aspects contributed. Our results appear to be in line with a recent meta-analysis on prognostic factors for IMMRP outcome, demonstrating that both pre-treatment general emotional distress and pain-specific cognitive behavioural factors are related to worse long-term (\>6 months) physical functioning \[[@B84-jcm-08-00905]\]. Unfortunately, these regressions cannot be used clinically, since they only explained 8% of variations in MIS. Although the prediction does not work clinically, this and a previous study from our group give clear indications that patients with a severe clinical situation benefit from IMMRP \[[@B34-jcm-08-00905]\].

4.1. Important Clinical Implications {#sec4dot1-jcm-08-00905}
------------------------------------

Outcomes of IMMRP in real-life practice settings agree with the conclusions from SRs. Partly in contrast to SRs, this registry study of patients managed within specialist care found that pain intensity was positively affected because of IMMRP. It was also obvious that not all patients benefit from IMMRP. Hence, there is a need to develop better matching between clinical presentation and participation in MMRP in real-life practice settings. Moreover, the intercorrelations of most changes in outcomes also opens up the possibility of reducing the number of outcome variables and hereby reduce the burden upon patients included in the SQRP.

4.2. Strengths and Limitations {#sec4dot2-jcm-08-00905}
------------------------------

This study's strengths include a large number of patients with complex chronic pain conditions with a nation-wide representation. However, these patients were referred to specialist clinics and thus represent a selection of the most difficult cases, so our results cannot be generalised to other settings. Another strength was the use of MVDA methods such as PCA and OPLS to handle correlation patterns, repeated measures, and regressions when there were obvious risks for multicollinearity. Changes in the social context may have changed and influenced the longitudinal analyses; however, we used validated and well-known instruments. Repeated evaluations using PROM questionnaires in treatment studies may be problematic \[[@B85-jcm-08-00905]\]. Thus, the changes that the patient undergo because of the intervention (i.e., IMMRP) may affect the interpretations of the questions when presented at follow-up. The fact that no control group or treatment-as-usual group was available, which ethically is complicated to arrange for a registry of real-life practice patients, might have influenced our interpretation of changes after IMMRP. Data for the time period 2008--2016 from the SQRP was used in the present study, and changes in the content of IMMRP may have occurred. Unfortunately, no data concerning such changes are available.

5. Conclusions {#sec5-jcm-08-00905}
==============

This large-scale study of IMMRPs in real life practise settings demonstrates significant outcome changes in almost all measures. Most short-term and long-term effect sizes were small, but interestingly, moderate long-term effect sizes were demonstrated for pain, pain interference in daily life, and perceived health. In addition, patients reporting higher levels of perceived disability and suffering displayed greater improvement.
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ACT

Acceptance Commitment Therapy

ANOVA

Analysis of Variance

BPS

biopsychosocial

CBT

Cognitive Behavioral Therapy

Change-pain

positive change in pain

Change-life situation

change in ability to handle life situations in general

CI

confidence interval

CV-ANOVA

ANOVA of the cross-validated residuals

ES

effect size

EQ-5D

European Quality of Life instrument

EQ-5D-index

index of EQ-5D based on five items

EQ-VAS

health scale of EQ-5D

FU

follow-up

GRADE

Grading of Recommendations Assessment, Development and Evaluation

HADS

Hospital Anxiety and Depression Scale

HADS-A

Hospital Anxiety and Depression Scale---anxiety subscale

HADS-D

Hospital Anxiety and Depression Scale---depression subscale

HCA

Hierarchical Clustering Analysis

HR-QoL

health-related quality of life

IASP

the International Association for the Study of Pain

IMMPACT

the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

IMMRP

Interdisciplinary Multimodal Pain Rehabilitation Program

LR

logistic regression

MIS

Multivariate Improvement Score

MLR

multiple linear regression

MPI

Multidimensional Pain Inventory

MPI-Pain-severity

MPI subscale concerning pain severity

MPI-Pain-interfer

MPI subscale concerning pain-related interference

MPI-Distress

MPI-SocSupp affective distress

MPI-LifeCon

MPI subscale concerning life control

MPI-SocSupp

MPI subscale concerning social support

MPI-Punish

MPI subscale concerning punishing responses

MPI-Solict

MPI subscale concerning solicitous responses

MPI-Distract

MPI subscale concerning distracting responses

MPI-GAI

MPI subscale General Activity Index

MVDA

advanced multivariate analysis

NIPALS

Non-linear Iterative Partial Least Squares

NRS

Numeric Rating Scale

NRS-7days

average pain intensity the last week

OPLS

Orthogonal Partial Least Square Regression

Outside-Europe

born outside Europe

PBE

practice-based evidence

P(corr)

loading scaled as a correlation coefficient between −1.0 and +1.0

PCA

Principal Component Analysis

PLS-DA

partial least square discriminant analysis

PRI

Pain Region Index

PROM

patient reported outcome measures

RCT

Randomised Controlled Trial

SQRP

Swedish Quality Registry for Pain Rehabilitation

sf36

Short Form Health Survey

sf36-pf

sf36 subscale concerning physical functioning

sf36-rp

sf36 subscale concerning role limitations due to physical functioning

sf36-bp

sf36 subscale concerning bodily pain

sf36-gh

sf36 subscale concerning general health

sf36-vt

sf36 subscale concerning vitality

sf36-sf

sf36 subscale concerning social functioning

sf36-re

sf36 subscale concerning role limitations due to emotional problems

sf36-mh

sf36 subscale concerning mental health

SR

systematic review

University

University education

VAPAIN

Validation and Application of a patient-relevant core set of outcome domains to assess multimodal PAIN therapy

VIP

variable influence on projection
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Loading plot of changes (pre-IMMRP vs. 12-month follow-up) in the 22 outcome variables---i.e., the relationships between the changes (**a**) and score plot ((**b**); the relationships between the patients). diff = change in a certain variable; NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey; For explanations of the subscale abbreviations, see Methods.
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Continuous background variables; mean ± SD and 95% confidence intervals (95% CI).

  --------------------------------------------------------------------
  Variables                  Mean ± SD     95% CI\       95% CI\
                                           Lower Bound   Upper Bound
  -------------------------- ------------- ------------- -------------
  Age (years)                43.2 ± 10.7   43.3          43.9

  Days no work               1055 ± 2461   968           1095

  Pain duration              3057 ± 3341   2970          3170

  Persistent pain duration   2368 ± 2980   2239          2414

  PRI                        15.4 ± 8.6    15.1          15.6
  --------------------------------------------------------------------

Notes: SD = standard deviation; CI = confidence intervals; PRI = Pain Region Index.

jcm-08-00905-t002_Table 2

###### 

Outcome variables at baseline (pre-IMMRP) and immediately after IMMRP (post-IMMRP). Statistical comparisons are presented furthest to the right together with effects sizes (i.e., Cohen's d). Effect sizes in bold were moderate, i.e., Cohen's d ≥ 0.50. IMMRP: interdisciplinary multimodal pain rehabilitation programs.

  Baseline vs. After IMMRP            Pre-IMMRP           Post-IMMRP                     
  -------------------------- -------- ----------- ------- ------------ ------- --------- ----------
  NRS-7days                  14,146   6.86        1.72    5.95         2.09    \<0.001   0.45
  HADS-A                     14,774   9.00        4.76    7.78         4.55    \<0.001   0.32
  HADS-D                     14,772   8.49        4.44    6.70         4.31    \<0.001   0.47
  MPI-Pain-severity          14,692   4.39        0.93    3.87         1.16    \<0.001   **0.52**
  MPI-Pain-interfer          14,552   4.38        1.02    3.94         1.19    \<0.001   0.49
  MPI-LifeCon                14,687   2.72        1.10    3.30         1.18    \<0.001   0.47
  MPI-Distress               14,697   3.46        1.26    2.89         1.38    \<0.001   0.42
  MPI-Socsupp                14,618   4.16        1.34    3.95         1.35    \<0.001   0.21
  MPI-punish                 13,054   1.74        1.36    1.72         1.33    0.037     0.02
  MPI-protect                12,999   2.98        1.40    2.85         1.38    \<0.001   0.12
  MPI-distract               13,048   2.54        1.19    2.56         1.17    0.043     0.02
  MPI-GAI                    14,676   2.44        0.84    2.63         0.82    \<0.001   0.26
  EQ-5D-index                13,989   0.26        0.31    0.39         0.33    \<0.001   0.40
  EQ-VAS                     13,777   41.22       19.09   50.99        21.38   \<0.001   0.44
  sf36-pf                    14,253   52.76       20.58   57.67        21.17   \<0.001   0.30
  sf36-rp                    13,945   12.53       24.40   22.46        33.12   \<0.001   0.30
  sf36-bp                    14,268   24.36       14.49   32.96        17.41   \<0.001   **0.52**
  sf36-gh                    13,988   41.70       20.22   46.69        21.88   \<0.001   0.29
  sf36-vt                    14,206   23.95       18.48   35.67        22.76   \<0.001   **0.54**
  sf36-sf                    14,229   47.29       25.19   54.93        25.91   \<0.001   0.30
  sf36-re                    13,701   42.77       42.92   51.15        43.48   \<0.001   0.18
  sf36-mh                    14,194   55.03       21.35   62.55        21.55   \<0.001   0.38

NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey. For explanations of the subscale abbreviations, see Methods.
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###### 

Outcome variables at baseline (pre-IMMRP) and at the 12-month follow-up (FU). Statistical comparisons are presented furthest to the right together with effects sizes (i.e., Cohen's d). Effect sizes in bold were moderate (i.e., Cohen's d ≥ 0.50).

  -------------------------------------------------------------------------------------------
  Baseline vs.\        Pre IMMRP           12-Month FU                             
  12-Month Follow-Up                                                               
  -------------------- ----------- ------- ------------- ------- ------- --------- ----------
  NRS-7days            8568        6.84    1.72          5.78    2.32    \<0.001   0.47

  HADS-A               8865        8.73    4.69          7.38    4.70    \<0.001   0.33

  HADS-D               8865        8.18    4.37          6.74    4.66    \<0.001   0.35

  MPI-Pain-severity    8904        4.36    0.91          3.71    1.33    \<0.001   **0.56**

  MPI-Pain-interfer    8829        4.34    1.02          3.73    1.37    \<0.001   **0.54**

  MPI-LifeCon          8871        2.77    1.10          3.28    1.27    \<0.001   0.40

  MPI-Distress         8889        3.42    1.27          2.92    1.45    \<0.001   0.35

  MPI-Socsupp          8830        4.17    1.33          3.77    1.42    \<0.001   0.35

  MPI-punish           7824        1.69    1.34          1.69    1.35    0.676     0.01

  MPI-protect          7784        2.96    1.39          2.78    1.40    \<0.001   0.16

  MPI-distract         7811        2.52    1.17          2.45    1.17    \<0.001   0.06

  MPI-GAI              8859        2.47    0.83          2.64    0.86    \<0.001   0.20

  EQ-5D-index          8844        0.27    0.31          0.44    0.34    \<0.001   **0.50**

  EQ-VAS               8607        41.90   19.29         52.96   22.87   \<0.001   0.46

  sf36-pf              8459        53.07   20.30         59.73   22.57   \<0.001   0.36

  sf36-rp              8301        13.07   24.91         27.74   36.32   \<0.001   0.39

  sf36-bp              8458        24.60   14.11         35.41   20.05   \<0.001   **0.56**

  sf36-gh              8342        42.59   20.49         47.35   23.52   \<0.001   0.25

  sf36-vt              8441        24.96   18.79         34.41   23.85   \<0.001   0.41

  sf36-sf              8459        48.95   25.50         57.66   27.05   \<0.001   0.32

  sf36-re              8159        44.69   43.17         55.60   43.53   \<0.001   0.22

  sf36-mh              8435        56.34   21.15         62.70   22.53   \<0.001   0.30
  -------------------------------------------------------------------------------------------

NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36); Health Survey; FU = Follow-up. For explanations of the subscale abbreviations see Methods.

jcm-08-00905-t004_Table 4

###### 

Estimations of pain situation (Change-pain) and in the ability to handle life situation in general (Change-life situation) made immediately after IMMRP (post-IMMRP) and at the 12-month FU.

  Change-Pain                               Post-IMMRP                 12-Month FU
  ------------------------------- --------- ---------------- --------- -----------------
  0\. Markedly increased pain     447       3.2              225       2.6
  1\. Partially increased pain    1517      11               590       6.9
  2\. No change                   4008      29.1             2905      34
  3\. Partially diminished pain   6178      44.9             3662      42.8
  4\. Markedly diminished pain    1607      11.7             1174      13.7
  Total                           13 757    100              8 556     100
  **Change-Life situation**                 **Post-IMMRP**             **12-Month FU**
                                  ***n***   **%**            ***n***   **%**
  0\. Markedly deteriorated       74        0.5              108       1.3
  1\. Partially deteriorated      248       1.8              282       3.3
  2\. No change                   1923      13.9             1615      18.8
  3\. Partially improved          8412      60.9             4628      54
  4\. Markedly improved           3161      22.9             1937      22.6
  Total                           13 818    100              8 570     100

FU = Follow-up.

jcm-08-00905-t005_Table 5

###### 

Principal component analysis (PCA) of changes pre-IMMRP vs. post-IMMRP (left part) and pre-IMMRP vs. 12-month FU (right part). The significant components (p) are shown. Absolute loadings ≥ 0.25 are shown in bold to facilitate interpretation. Changes in outcomes are calculated so that a positive value indicates an improvement.

                           Changes Pre-IMMRP vs. Post-IMMRP   Changes Pre-IMMRP vs. 12-Month FU              
  ------------------------ ---------------------------------- ----------------------------------- ---------- -----------
                           p\[1\]                             p\[1\]                              p\[2\]     p\[3\]
  diff-NRS-7days           0.23                               0.23                                −0.15      **0.29**
  diff-HADS-A              0.23                               0.22                                0.19       **−0.33**
  diff-HADS-D              **0.26**                           **0.25**                            0.17       −0.24
  diff-MPI-Pain-sever      **0.27**                           **0.27**                            −0.16      0.26
  diff-MPI-Pain-interfer   **0.26**                           **0.28**                            −0.11      0.10
  diff-MPI-LifeCon         **0.26**                           **0.25**                            0.09       −0.05
  diff-MPI-distress        **0.27**                           **0.26**                            0.13       −0.21
  diff-MPI-SOCsupp         −0.03                              −0.07                               **0.41**   0.21
  diff-MPI-punish          0.07                               0.08                                **0.32**   0.11
  diff-MPI-protect         −0.02                              −0.02                               **0.51**   **0.33**
  diff-MPI-distract        0.01                               0.00                                **0.45**   **0.36**
  diff-MPI-GAI             0.12                               0.15                                0.00       0.07
  diff-EQ-5D-index         0.22                               0.22                                −0.07      0.12
  diff-EQ-VAS              0.22                               0.23                                −0.03      0.09
  diff-sf36-pf             0.20                               0.21                                −0.14      0.20
  diff-sf36-rp             0.19                               0.21                                −0.10      0.17
  diff-sf36-bp             **0.26**                           **0.27**                            −0.15      **0.25**
  diff-sf36-gh             0.21                               0.21                                0.02       0.02
  diff-sf36-vt             **0.27**                           **0.26**                            0.03       −0.03
  diff-sf36-sf             **0.25**                           0.24                                0.05       −0.09
  diff-sf36-re             0.18                               0.17                                0.13       **−0.26**
  diff-sf36-mh             **0.27**                           **0.25**                            0.21       **−0.30**
  R^2^                     0.31                               0.36                                0.10       0.06
  Q^2^                     0.25                               0.31                                0.04       0.02
  N                        14,666                             8851                                           

diff = change in a certain variable; *p* = principal component; NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey; FU = Follow-up. For explanations of the subscale abbreviations see Methods.

jcm-08-00905-t006_Table 6

###### 

Clusters from hierarchical clustering analysis (HCA) based on Multivariate Improvement Score (MIS) (*t*-scores) of the first component of the PCA for the changes in outcomes from pre-IMMRP to post-IMMRP (denoted ***MIS post-IMMRP***). To facilitate understanding, the changes for all the outcomes are shown (mean, SD, and 95% confidence interval). The two bottom rows show the estimations of changes (not included in PCA and the calculation of MIS).

                           Cluster 1 (15.0%)   Cluster 2 (54.1%)   Cluster 3 (30.8%)                                                                                                                                                                                  
  ------------------------ ------------------- ------------------- ------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------- ------------ ------------- ------------- --------------- ------------------------
  ***MIS post-IMMRP***     ***2205***          ***4.37***          ***1.61***          ***4.31***   ***4.44***   ***7938***   ***0.33***   ***1.08***   ***0.30***   ***0.35***   ***4523***   ***−2.74***   ***1.16***   ***−2.78***   ***−2.71***   ***\<0.001***   ***all different***
  diff-NRS-7days           2086                3.04                2.05                2.95         3.13         7511         1.01         1.69         0.97         1.04         4267         −0.28         1.58         −0.32         −0.23         \<0.001         all different
  diff-HADS-A              2191                5.12                3.72                4.96         5.28         7873         1.59         3.08         1.52         1.66         4458         −1.30         3.24         −1.39         −1.20         \<0.001         all different
  diff-HADS-D              2188                5.93                3.55                5.78         6.08         7869         2.24         2.95         2.17         2.30         4462         −0.96         3.04         −1.05         −0.87         \<0.001         all different
  diff-MPI-Pain-severity   2185                1.77                1.02                1.73         1.82         7874         0.56         0.74         0.54         0.58         4500         −0.17         0.69         −0.19         −0.15         \<0.001         all different
  diff-MPI-Pain-interfer   2173                1.53                0.99                1.49         1.57         7811         0.50         0.70         0.48         0.51         4453         −0.17         0.66         −0.18         −0.15         \<0.001         all different
  diff-MPI-LideCon         2189                1.94                1.05                1.89         1.98         7861         0.71         0.96         0.69         0.73         4491         −0.33         0.99         −0.36         −0.30         \<0.001         all different
  diff-MPI-distress        2187                2.18                1.17                2.13         2.23         7869         0.71         1.02         0.69         0.73         4487         −0.46         1.05         −0.49         −0.43         \<0.001         all different
  diff-MPI-SOCsupp         2180                −0.34               1.12                −0.39        −0.30        7828         −0.24        0.98         −0.26        −0.21        4462         −0.11         0.98         −0.14         −0.08         \<0.001         all different
  diff-MPI-punish          1991                0.39                1.20                0.34         0.45         7016         0.04         1.12         0.02         0.07         4008         −0.20         1.15         −0.24         −0.17         \<0.001         all different
  diff-MPI-protect         1988                −0.18               1.17                −0.23        −0.13        6984         −0.14        1.00         −0.17        −0.12        3989         −0.05         1.05         −0.09         −0.02         \<0.001         cl1 NE cl2, cl2 NE cl3
  diff-MPI-distract        1992                0.11                1.10                0.06         0.16         7012         0.00         0.96         −0.03        0.02         4006         0.01          1.03         −0.02         0.04          \<0.001         cl1 NE cl2, cl3
  diff-MPI-GAI             2187                0.57                0.82                0.53         0.60         7866         0.23         0.68         0.21         0.24         4489         −0.06         0.69         −0.08         −0.03         \<0.001         all different
  diff-EQ-5D-index         2105                0.44                0.30                0.43         0.45         7494         0.16         0.28         0.15         0.17         4205         −0.07         0.28         −0.08         −0.06         \<0.001         all different
  diff-EQ-VAS              2068                30.51               19.66               29.66        31.36        7409         11.61        18.58        11.19        12.03        4126         −3.84         19.15        −4.42         −3.25         \<0.001         all different
  diff-sf36-pf             2147                18.74               16.97               18.02        19.46        7644         6.02         13.63        5.72         6.33         4324         −3.83         14.22        −4.25         −3.40         \<0.001         all different
  diff-sf36-rp             2110                39.93               39.28               38.25        41.60        7513         10.46        29.70        9.79         11.13        4215         −5.96         25.56        −6.74         −5.19         \<0.001         all different
  diff-sf36-bp             2146                28.04               16.27               27.35        28.73        7663         9.72         12.96        9.43         10.01        4323         −2.93         12.38        −3.30         −2.56         \<0.001         all different
  diff-sf36-gh             2126                21.06               17.59               20.31        21.81        7529         6.05         14.51        5.72         6.37         4235         −4.89         14.57        −5.33         −4.45         \<0.001         all different
  diff-sf36-vt             2139                37.45               18.74               36.65        38.24        7626         13.58        17.26        13.19        13.96        4311         −4.20         16.16        −4.69         −3.72         \<0.001         all different
  diff-sf36-sf             2146                34.26               22.17               33.32        35.20        7652         10.12        20.39        9.66         10.58        4324         −9.86         21.10        −10.49        −9.23         \<0.001         all different
  diff-sf36-re             2087                43.52               44.58               41.60        45.43        7390         11.98        43.21        11.00        12.97        4121         −15.81        42.02        −17.09        −14.52        \<0.001         all different
  diff-sf36-mh             2139                29.61               17.48               28.86        30.35        7620         10.12        14.90        9.78         10.45        4307         −8.01         15.89        −8.49         −7.54         \<0.001         all different
  Change-Pain              2059                3.28                0.69                3.25         3.31         7280         2.53         0.87         2.51         2.55         4015         2.08          0.93         2.05          2.11          \<0.001         all different
  Change-Life situation    2067                3.51                0.58                3.48         3.53         7315         3.07         0.63         3.05         3.08         4032         2.76          0.72         2.74          2.79          \<0.001         all different

LB = Lower Bound; UB = Upper Bound; diff = change in a certain variable; NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey. For explanations of the subscale abbreviations, see Methods.
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###### 

Clusters from HCA based on MIS (*t*-scores) of the first component of the PCA for the changes in outcomes from pre-IMMRP to 12-month FU (denoted as ***MIS 12-m FU***). To facilitate understanding, the changes for all the outcomes are shown (mean, SD, and 95% confidence interval). The two bottom rows show the estimations of changes (not included in PCA and the calculation of MIS).

                           Cluster 1 (12.4%)   Cluster 2 (46.6%)   Cluster 3 (41.0%)                                                                                                                                                                                  
  ------------------------ ------------------- ------------------- ------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------- ------------ ------------- ------------- --------------- -----------------------
  ***MIS -12-m FU***       ***1099***          ***5.01***          ***1.78***          ***4.90***   ***5.11***   ***4123***   ***0.78***   ***1.35***   ***0.74***   ***0.82***   ***3629***   ***−2.43***   ***1.39***   ***−2.47***   ***−2.38***   ***\<0.001***   ***all different***
  diff-NRS-7days           1031                3.67                2.15                3.54         3.80         3876         1.46         1.89         1.40         1.52         3435         −0.16         1.66         −0.21         −0.10         \<0.001         all different
  diff-HADS-A              1095                5.72                3.84                5.49         5.95         4087         2.06         3.34         1.96         2.16         3588         −0.80         3.53         −0.91         −0.68         \<0.001         all different
  diff-HADS-D              1096                6.13                3.75                5.90         6.35         4086         2.39         3.13         2.29         2.48         3588         −1.05         3.39         −1.16         −0.94         \<0.001         all different
  diff-MPI-Pain-severity   1092                2.30                1.14                2.24         2.37         4108         0.88         0.90         0.85         0.91         3619         −0.09         0.76         −0.12         −0.07         \<0.001         all different
  diff-MPI-Pain-interfer   1092                2.30                1.14                2.24         2.37         4108         0.88         0.90         0.85         0.91         3589         −0.14         0.74         −0.17         −0.12         \<0.001         all different
  diff-MPI-LifeCon         1086                2.27                1.10                2.21         2.34         4076         0.83         0.85         0.81         0.86         3604         −0.25         1.05         −0.28         −0.21         \<0.001         all different
  diff-MPI-distress        1091                2.10                1.10                2.03         2.16         4095         0.75         1.00         0.71         0.78         3618         −0.38         1.13         −0.41         −0.34         \<0.001         all different
  diff-MPI-SOCsupp         1086                −0.69               1.25                −0.77        −0.62        4081         −0.60        1.16         −0.64        −0.57        3583         −0.10         1.04         −0.13         −0.07         \<0.001         all different
  diff-MPI-punish          979                 0.57                1.19                0.50         0.65         3633         −0.02        1.22         −0.06        0.02         3194         −0.13         1.22         −0.18         −0.09         \<0.001         all different
  diff-MPI-protect         980                 −0.23               1.24                −0.31        −0.15        3616         −0.35        1.20         −0.39        −0.31        3173         0.03          1.09         −0.01         0.06          \<0.001         all different
  diff-MPI-distract        981                 0.02                1.15                −0.05        0.10         3627         −0.22        1.09         −0.25        −0.18        3188         0.08          1.02         0.04          0.11          \<0.001         CL NE cl3, cl2 NE cl3
  diff-MPI-GAI             1090                0.76                0.95                0.70         0.82         4094         0.26         0.73         0.23         0.28         3613         −0.11         0.73         −0.14         −0.09         \<0.001         all different
  diff-EQ-5D-index         1048                0.53                0.30                0.51         0.55         3886         0.25         0.30         0.24         0.26         3351         −0.04         0.30         −0.05         −0.03         \<0.001         all different
  diff-EQ-VAS              1022                36.06               20.47               34.80        37.32        3833         16.27        19.82        15.64        16.89        3316         −3.31         19.66        −3.98         −2.64         \<0.001         all different
  diff-sf36-pf             1054                26.77               19.09               25.61        27.92        3953         10.00        15.13        9.53         10.47        3445         −3.31         15.24        −3.81         −2.80         \<0.001         all different
  diff-sf36-rp             1043                57.34               39.51               54.94        59.74        3889         19.15        34.30        18.07        20.22        3365         −3.69         27.14        −4.60         −2.77         \<0.001         all different
  diff-sf36-bp             1054                37.44               19.56               36.26        38.63        3954         14.29        14.79        13.83        14.75        3444         −1.33         13.03        −1.76         −0.89         \<0.001         all different
  diff-sf36-gh             1044                25.26               19.09               24.10        26.42        3908         7.78         16.33        7.26         8.29         3388         −5.04         15.87        −5.57         −4.50         \<0.001         all different
  diff-sf36-vt             1054                40.71               19.72               39.52        41.91        3951         13.32        17.83        12.77        13.88        3433         −4.60         16.67        −5.16         −4.05         \<0.001         all different
  diff-sf36-sf             1053                40.73               23.26               39.32        42.14        3958         14.43        21.21        13.77        15.09        3445         −7.66         22.38        −8.40         −6.91         \<0.001         all different
  diff-sf36-re             1031                53.10               44.27               50.40        55.81        3849         17.22        45.08        15.79        18.64        3277         −9.79         45.59        11.35         −8.22         \<0.001         all different
  diff-sf36-mh             1054                32.77               18.81               31.64        33.91        3948         10.62        16.33        10.11        11.13        3430         −6.66         17.25        −7.24         −6.09         \<0.001         all different
  Change-Pain              1049                3.32                0.74                3.28         3.37         3887         2.72         0.81         2.69         2.75         3373         2.20          0.85         2.17          2.22          \<0.001         all different
  Change-Life situation    1049                3.52                0.64                3.48         3.56         3901         3.05         0.70         3.03         3.08         3375         2.62          0.83         2.59          2.65          \<0.001         all different

LB = Lower Bound; UB = Upper Bound; diff = change in a certain variable; NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey. For explanations of the subscale abbreviations, see Methods.
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###### 

Pre-IMMRP values for the three clusters based on MIS obtained post-IMMRP.

                      Cluster 1   Cluster 2   Cluster 3                                                                                               
  ------------------- ----------- ----------- ----------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------- ------------------------
  Gender              2205        0.22        0.41        0.20   0.23   7938   0.24   0.43   0.23   0.25   4523   0.25   0.43   0.24   0.26   0.014   NA
  Age                 2205        42.7        11.2        42.2   43.2   7938   43.5   10.7   43.3   43.8   4523   43.0   10.6   42.7   43.3   0.001   cl1 NE cl3, cl2 NE cl3
  Outside-Europe      2185        0.11        0.31        0.09   0.12   7877   0.10   0.30   0.09   0.10   4484   0.11   0.32   0.10   0.12   0.011   NA
  University          2168        0.28        0.45        0.26   0.29   7826   0.26   0.44   0.25   0.27   4445   0.23   0.42   0.22   0.24   0.000   cl1 NE cl2, cl2 NE cl3
  Days no work        716         889         2912        675    1102   2976   1037   2311   954    1120   1774   1152   2502   1036   1269   0.045   NA
  PRI                 2205        13.8        8.3         13.4   14.1   7938   14.4   8.3    14.2   14.6   4523   14.5   8.3    14.3   14.7   0.002   NA
  NRS-7days           2158        7.1         1.7         7.0    7.2    7801   6.9    1.7    6.8    6.9    4440   6.7    1.7    6.7    6.8    0.000   all different
  HADS-A              2199        10.4        4.7         10.2   10.6   7891   9.0    4.7    8.9    9.1    4494   8.2    4.6    8.1    8.4    0.000   all different
  HADS-D              2197        9.6         4.4         9.4    9.8    7892   8.6    4.4    8.5    8.7    4494   7.7    4.3    7.6    7.9    0.000   all different
  MPI-Pain-severity   2193        4.5         0.9         4.5    4.6    7895   4.4    0.9    4.4    4.4    4510   4.3    0.9    4.3    4.3    0.000   all different
  MPI-Pain-interfer   2187        4.6         1.0         4.6    4.6    7853   4.4    1.0    4.4    4.4    4485   4.3    1.0    4.2    4.3    0.000   all different
  MPI-LifeCon         2195        2.4         1.1         2.4    2.5    7880   2.7    1.1    2.7    2.7    4502   2.9    1.1    2.9    3.0    0.000   all different
  MPI-Distress        2191        3.9         1.2         3.9    4.0    7891   3.5    1.3    3.5    3.5    4502   3.2    1.3    3.1    3.2    0.000   all different
  MPI-Socsupp         2190        4.2         1.4         4.2    4.3    7861   4.2    1.3    4.1    4.2    4488   4.1    1.4    4.1    4.2    0.005   NA
  MPI-punish          2069        1.9         1.5         1.8    1.9    7319   1.8    1.4    1.7    1.8    4169   1.7    1.3    1.6    1.7    0.000   all different
  MPI-protect         2065        3.0         1.5         2.9    3.1    7295   2.9    1.4    2.9    3.0    4158   3.0    1.4    2.9    3.0    0.136   NA
  MPI-distract        2069        2.6         1.2         2.5    2.6    7312   2.5    1.2    2.5    2.5    4168   2.5    1.2    2.5    2.6    0.075   NA
  MPI-GAI             2193        2.4         0.8         2.4    2.4    7885   2.4    0.8    2.4    2.5    4500   2.5    0.8    2.5    2.5    0.000   cl1 NE cl2, cl2 NE cl3
  EQ-5D-index         2126        0.2         0.3         0.2    0.2    7587   0.3    0.3    0.2    0.3    4277   0.3    0.3    0.3    0.3    0.000   all different
  EQ-VAS              2097        38.0        18.2        37.2   38.8   7529   40.7   19.0   40.3   41.1   4224   43.9   19.4   43.3   44.5   0.000   all different
  sf36-pf             2151        52.1        21.0        51.2   52.9   7683   52.8   20.6   52.3   53.2   4349   53.2   20.2   52.6   53.8   0.119   NA
  sf36-rp             2139        9.0         19.8        8.2    9.9    7629   11.8   23.8   11.3   12.4   4283   15.3   26.8   14.5   16.1   0.000   all different
  sf36-bp             2151        21.1        13.8        20.5   21.7   7694   24.1   14.3   23.8   24.4   4347   26.4   14.6   26.0   26.8   0.000   all different
  sf36-gh             2139        39.8        20.0        38.9   40.6   7610   41.4   20.1   41.0   41.9   4299   43.3   20.4   42.7   43.9   0.000   all different
  sf36-vt             2151        19.7        16.6        19.0   20.4   7679   23.3   18.4   22.9   23.7   4347   27.3   19.0   26.7   27.8   0.000   all different
  sf36-sf             2151        40.0        23.7        39.0   41.0   7690   46.6   24.9   46.1   47.2   4348   52.1   25.3   51.4   52.9   0.000   all different
  sf36-re             2126        30.6        39.6        28.9   32.2   7549   41.6   42.6   40.7   42.6   4220   50.6   43.6   49.3   51.9   0.000   all different
  sf36-mh             2151        47.3        20.7        46.5   48.2   7672   54.5   21.2   54.0   54.9   4343   60.1   20.5   59.4   60.7   0.000   all different

LB = Lower Bound; UB = Upper Bound; NA = not applicable; NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey; PRI = Pain Region Index. For explanations of the subscale abbreviations, see Methods.
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###### 

Pre-IMMRP values for the three clusters based on MIS obtained at 12-month FU.

                      Cluster 1   Cluster 2   Cluster 3                                                                                                 
  ------------------- ----------- ----------- ----------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ --------- ----------------------------------
  Gender              1099        0.24        0.43        0.21   0.26   4123   0.21   0.41   0.20   0.22   3629   0.25   0.43   0.24   0.27   \<0.001   all different
  Age                 1099        41.9        11.1        41.2   42.5   4123   43.7   11.1   43.4   44.0   3629   44.2   10.4   43.8   44.5   \<0.001   all different
  Outside-Europe      1088        0.09        0.29        0.07   0.11   4091   0.08   0.28   0.08   0.09   3606   0.10   0.30   0.09   0.11   0.012     NA
  University          1079        0.29        0.45        0.26   0.31   4060   0.27   0.45   0.26   0.29   3567   0.23   0.42   0.21   0.24   \<0.001   all different except cl2 vs. cl3
  Days no work        358         661         2587        392    930    1409   1046   2339   923    1168   1323   1270   2604   1130   1411   \<0.001   all different
  PRI                 1099        12.8        8.0         12.3   13.2   4123   14.2   8.3    14.0   14.5   3629   14.8   8.3    14.5   15.1   \<0.001   all different
  NRS-7days           1071        7.0         1.7         6.9    7.1    4049   6.8    1.7    6.8    6.9    3574   6.8    1.7    6.8    6.9    0.049     NA
  HADS-A              1096        9.7         4.7         9.4    10.0   4101   8.7    4.7    8.6    8.9    3606   8.4    4.6    8.3    8.6    \<0.001   all different
  HADS-D              1096        8.8         4.4         8.6    9.1    4102   8.2    4.3    8.1    8.3    3606   8.0    4.4    7.9    8.1    \<0.001   all different
  MPI-Pain-severity   1094        4.5         0.9         4.4    4.5    4114   4.4    0.9    4.3    4.4    3625   4.3    0.9    4.3    4.4    \<0.001   cl1NE cl2, cl2 NE cl1, cl3
  MPI-Pain-interfer   1093        4.5         0.9         4.5    4.6    4101   4.4    1.0    4.3    4.4    3609   4.3    1.0    4.2    4.3    \<0.001   all different
  MPI-LifeCon         1096        2.5         1.1         2.5    2.6    4113   2.8    1.1    2.7    2.8    3614   2.9    1.1    2.8    2.9    \<0.001   all different
  MPI-Distress        1095        3.8         1.2         3.8    3.9    4114   3.4    1.3    3.4    3.5    3621   3.3    1.3    3.2    3.3    \<0.001   all different
  MPI-Socsupp         1090        4.3         1.3         4.2    4.4    4097   4.2    1.3    4.2    4.3    3604   4.1    1.4    4.1    4.1    \<0.001   all different
  MPI-punish          1036        1.8         1.4         1.7    1.9    3833   1.7    1.3    1.6    1.7    3355   1.7    1.3    1.7    1.8    0.047     NA
  IMP-protect         1038        3.0         1.4         2.9    3.1    3824   2.9    1.4    2.9    3.0    3341   2.9    1.4    2.9    3.0    0.583     NA
  MPI-distract        1039        2.6         1.2         2.5    2.6    3831   2.6    1.2    2.5    2.6    3352   2.5    1.2    2.4    2.5    0.003     NA
  MPI -GAI            1094        2.4         0.9         2.4    2.5    4108   2.5    0.8    2.5    2.5    3623   2.5    0.8    2.5    2.5    0.071     NA
  EQ-5D-index         1058        0.2         0.3         0.2    0.2    3935   0.3    0.3    0.3    0.3    3407   0.3    0.3    0.3    0.3    \<0.001   all different
  EQ-VAS              1037        39.2        18.2        38.1   40.3   3905   41.3   19.2   40.7   42.0   3389   43.1   19.6   42.4   43.7   \<0.001   all different
  sf36-pf             1056        51.9        20.4        50.7   53.1   3969   53.0   20.4   52.4   53.7   3459   53.4   20.1   52.7   54.1   0.120     NA
  sf36-rp             1053        8.5         20.6        7.2    9.7    3938   12.4   24.1   11.6   13.1   3417   15.3   26.9   14.4   16.2   \<0.001   all different
  sf36-bp             1058        21.5        13.3        20.7   22.3   3974   24.4   14.2   23.9   24.8   3461   25.9   14.0   25.4   26.3   \<0.001   all different
  sf36-gh             1052        43.1        21.0        41.8   44.4   3944   42.6   20.5   42.0   43.2   3424   42.3   20.3   41.7   43.0   0.556     NA
  sf36-vt             1058        21.4        17.8        20.3   22.5   3972   24.7   19.1   24.1   25.3   3452   26.3   18.6   25.7   26.9   \<0.001   all different
  sf36-sf             1056        42.4        24.2        40.9   43.9   3976   48.2   25.6   47.4   49.0   3458   51.9   25.2   51.0   52.7   \<0.001   all different
  sf36-re             1046        32.1        40.3        29.7   34.5   3906   44.0   43.2   42.7   45.4   3363   49.1   43.2   47.6   50.5   \<0.001   all different
  sf36-mh             1058        49.6        20.9        48.3   50.9   3970   56.0   21.0   55.3   56.7   3451   58.7   20.9   58.0   59.4   \<0.001   all different

LB = Lower Bound; UB = Upper Bound; NA = not applicable; NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory; EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey; PRI = Pain Region Index. For explanations of the subscale abbreviations, see Methods.
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###### 

Orthogonal Partial Least Square Regressions (OPLS) regressions of MIS post-IMMRP (left part) and at 12-month FU (right part) using the variables pre-IMMRP as regressors. Variables in bold type are significant regressors.

  Post-IMMRP                 VIP        p(corr)     12-Month FU                    VIP        p(corr)
  -------------------------- ---------- ----------- ------------------------------ ---------- -----------
  **sf36-mh**                **1.80**   **−0.80**   **sf36-mh**                    **1.63**   **−0.62**
  **MPI-Distress**           **1.72**   **0.76**    **MPI-Distress**               **1.59**   **0.61**
  **HADS-D**                 **1.56**   **0.68**    **sf36-sf**                    **1.44**   **−0.53**
  **MPI-LifeCon**            **1.48**   **−0.65**   **sf36-re**                    **1.39**   **−0.54**
  **HADS-A**                 **1.48**   **0.65**    **MPI-LifeCon**                **1.35**   **−0.49**
  **sf36-sf**                **1.47**   **−0.63**   **HADS-D**                     **1.34**   **0.46**
  **sf36-re**                **1.43**   **−0.64**   **HADS-A**                     **1.28**   **0.46**
  **sf36-vt**                **1.27**   **−0.54**   **MPI-Pain-interfer**          **1.26**   **0.39**
  **MPI-Pain-interfer**      **1.26**   **0.45**    **Persistent-Pain-duration**   **1.16**   **−0.46**
  **EQ-5D-index**            **1.12**   **−0.41**   **Pain duration**              **1.15**   **−0.45**
  **sf36-bp**                **1.07**   **−0.35**   **EQ-5D-index**                **1.14**   **−0.37**
  **MPI-Pain-severity**      **1.05**   **0.28**    **sf36-bp**                    **1.11**   **−0.35**
  **EQ-VAS**                 **1.04**   **−0.39**   **sf36-vt**                    **1.11**   **−0.36**
  sf36-gh                    0.95       −0.30       MPI-Pain-severity              0.99       0.21
  NRS-7days                  0.88       0.20        EQ-VAS                         0.97       −0.28
  sf36-pf                    0.87       −0.07       sf36-rp                        0.96       −0.37
  sf36-rp                    0.80       −0.33       PRI                            0.95       −0.26
  PRI                        0.72       −0.09       sf36-gh                        0.87       −0.10
  MPI-GAI                    0.68       −0.20       NRS-7days                      0.81       0.11
  MPI-punish                 0.59       0.25        Days no work                   0.80       -0.31
  Outside-Europe             0.45       −0.01       sf36-pf                        0.76       −0.05
  Days no work               0.44       −0.16       Age                            0.75       −0.30
  University                 0.43       0.12        MPI-GAI                        0.72       −0.22
  Persistent Pain duration   0.42       −0.16       University                     0.54       0.18
  MPI-protect                0.41       −0.04       MPI-punish                     0.43       0.12
  Pain duration              0.38       −0.15       Outside-Europe                 0.39       −0.03
  MPI-Socsupp                0.32       −0.05       MPI-protect                    0.31       0.03
  MPI-distract               0.29       −0.01       MPI-distract                   0.26       0.06
  Age                        0.23       −0.10       MPI-Socsupp                    0.22       0.07
  Gender                     0.04       −0.01       Gender                         0.10       −0.04
  R^2^                       0.08                   R^2^                           0.08       
  Q^2^                       0.08                   Q^2^                           0.07       
  *n*                        14 657                 *n*                            7 976      
  CV-ANOVA *p*-value         \<0.001                CV-ANOVA *p*-value             \<0.001    

VIP (VIP \> 1.0 is significant) and p (corr) are reported for each regressor. The sign of p (corr) indicates the direction of the correlation with the dependent variable (+ = positive correlation; − = negative correlation). The four bottom rows of each regression report R^2^, Q^2^, and *p*-value of the CV-ANOVA and number of patients included in the regression (*n*). NRS-7days = Pain intensity as measured by a numeric rating scale for the previous seven days; HADS = Hospital Anxiety and Depression Scale; MPI = Multidimensional Pain Inventory EQ-5D-index = The index of the European quality of life instrument; EQ-VAS = The European quality of life instrument thermometer-like scale; sf36 = The Short Form (36) Health Survey; PRI = Pain Region Index. For explanations of the subscale abbreviations see Methods.
